NCT02657785View on ClinicalTrials.gov

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG

R-IDARAM plus intrathecal chemotherapy

R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors

lead

Navy General Hospital, Beijing

OTHER

NCT02657785 - Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | Biotech Hunter | Biotech Hunter